Jaguar health enters binding term sheet for $5 million non-dilutive financing transaction involving sale of royalty rights related to future potential crofelemer (mytesi) covid-related indication revenue stream

No royalty payments due for 36 months planned covid-related indication in long-hauler patients is the lead focus for crofelemer at napo eu, the exclusive target of the planned dragon spac, which is pursuing listing on aim italia company expects to provide additional updates regarding napo eu next week san francisco, ca / accesswire / march 5, 2021 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that the company has entered a binding agreement of terms (the "term sheet") for a third non-dilutive royalty financing transaction, pursuant to which jaguar would sell to the lender for an aggregate purchase price of $5 million (the "royalty purchase price") a royalty interest in future potential crofelemer (mytesi®) sales for the proposed covid-related indication in long-hauler patients (as defined below), for which the company is currently exploring the pathway of conditional marketing authorization in the european union. jaguar intends to use the proceeds from the proposed transaction to support regulatory activities associated with the company's development pipeline, including supporting the development program for crofelemer for the prophylaxis and/or symptomatic relief of inflammatory diarrhea, initially to be studied in a long-hauler covid-19 recovery patient population (the "covid-related indication").
JAGX Ratings Summary
JAGX Quant Ranking